Market Place
Sourcing Support
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
20 Jun 2024 //
GLOBENEWSWIRE
Vaxxinity retreats from `abusive relationship` of public market
15 May 2024 //
FIERCE BIOTECH
Vaxxinity To Voluntarily Delist, Deregister Class A Common Stock
19 Apr 2024 //
GLOBENEWSWIRE
Vaxxinity Issues Shareholder Letter
19 Apr 2024 //
GLOBENEWSWIRE
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology Meeting
28 Mar 2024 //
GLOBENEWSWIRE
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
Vaxxinity Announces Positive Data from Phase 1 Trial for Parkinson™s Disease
07 Mar 2024 //
GLOBENEWSWIRE
Vaxxinity™s Cholesterol Vaccine Candidate Successfully Lowers LDL-C
15 Feb 2024 //
GLOBENEWSWIRE
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
13 Feb 2024 //
GLOBENEWSWIRE
Vaxxinity Announces Research Collaboration on Active Immunotherapies
30 Jan 2024 //
GLOBENEWSWIRE
Vaxxinity Announces Collaboration on Space Medicine Research
18 Jan 2024 //
GLOBENEWSWIRE
Vaxxinity, UCF in collaboration to advance space medicine
18 Jan 2024 //
FIERCE BIOTECH
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
13 Nov 2023 //
GLOBENEWSWIRE
Vaxxinity Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Vaxxinity to Present at Upcoming Investor Conferences in September
29 Aug 2023 //
GLOBENEWSWIRE
Vaxxinity Announces Publication of UB-311 Data from Ph 2a in Alzheimer`s Disease
10 Aug 2023 //
GLOBENEWSWIRE
Vaxxinity Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President
27 Jul 2023 //
GLOBENEWSWIRE
Vaxxinity Shows Target Engagement of Toxic Alpha-Synuclein in Parkinsons Patients
17 Jul 2023 //
GLOBENEWSWIRE
Vaxxinity celebrates trial success in early Parkinson’s therapy
23 Jun 2023 //
CLINICAL TRIALS ARENA
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Ph1 Trial
22 Jun 2023 //
GLOBENEWSWIRE
Vaxxinity Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology
28 Mar 2023 //
GLOBENEWSWIRE
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results
27 Mar 2023 //
GLOBENEWSWIRE
Vaxxinity seeks a partner to press ahead with Alzheimer`s med
27 Mar 2023 //
FIERCE BIOTECH
Vaxxinity Joins TransCelerate Research and Development Consortium
21 Mar 2023 //
GLOBENEWSWIRE
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401
20 Mar 2023 //
GLOBENEWSWIRE
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
02 Mar 2023 //
GLOBENEWSWIRE
Vaxxinity Announces Board Appointments and Establishes Headquarters in Florida
01 Feb 2023 //
GLOBENEWSWIRE
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
Vaxxinity Announces Positive Topline Ph3 COVID-19 Booster Data for UB-612
02 Dec 2022 //
GLOBENEWSWIRE
Texas biotech’s COVID booster takes on competitors in phase 3
02 Dec 2022 //
FIERCEBIOTECH
Vaxxinity to Host First Analyst and R&D Day in New York City in November
03 Nov 2022 //
GLOBENEWSWIRE
Vaxxinity to Present at Upcoming Investor Conferences in November
01 Nov 2022 //
GLOBENEWSWIRE
Vaxxinity concludes subject enrolment in Phase III Covid-19 vaccine trial
25 Oct 2022 //
CLINICALTRIALSARENA
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313
13 Sep 2022 //
GLOBENEWSWIRE
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine MHRA (UK)
12 Sep 2022 //
GLOBENEWSWIRE
Vaxxinity to Present at Upcoming Investor Conferences in September
01 Sep 2022 //
GLOBENEWSWIRE
Vaxxinity Reports Q2 2022 Rusult and Provides Corporate Updates
11 Aug 2022 //
GLOBENEWSWIRE
Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference
04 Aug 2022 //
GLOBENEWSWIRE
Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering
02 Aug 2022 //
GLOBENEWSWIRE
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at AAIC 2022
01 Aug 2022 //
GLOBENEWSWIRE
Vaxxinity CEO Mei Mei Hu at White House Summit on Future of COVID-19 Vaccines
25 Jul 2022 //
GLOBENEWSWIRE
Vaxxinity to Participate at the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Vaxxinity Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Vaxxinity to Participate at the Bank of America Securities 2022 Conference
05 May 2022 //
GLOBENEWSWIRE
Vaxxinity Receives FDA FTD for UB-311 for Treatment of Alzheimer’s Disease
02 May 2022 //
GLOBENEWSWIRE
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial
28 Apr 2022 //
GLOBENEWSWIRE
CEPI to co-fund Vaxxinity`s pivotal Phase 3 UB-612 heterologous booster trial
06 Apr 2022 //
GLOBENEWSWIRE
Vaxxinity Begins Dosing in Phase 3 Study of Next-Gen COVID-19 Booster
28 Mar 2022 //
GLOBENEWSWIRE
Vaxxinity Reports Q4 and Full-Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
21 Mar 2022 //
GLOBENEWSWIRE
Vaxxinity Announces First Patient Dosed in Phase 1 Clinical Trial of UB-312
12 Jan 2022 //
GLOBENEWSWIRE
Vaxxinity Awarded Grant from Michael J. Fox Foundation for Parkinson’s Research
10 Jan 2022 //
GLOBENEWSWIRE
Vaxxinity makes a subdued Wall Street debut
12 Nov 2021 //
FIERCEBIOTECH
Maduro says Venezuela has secured funds to complete COVAX payment
13 Apr 2021 //
REUTRS
Asian countries seek vaccine supplies after India export curbs hit COVAX
30 Mar 2021 //
REUTERS
COVAX vaccine-sharing scheme to send out `hundreds of millions` of J&J shots
18 Mar 2021 //
REUTERS
COVAX vaccine-sharing scheme to send out `hundreds of millions` of J&J shots
17 Mar 2021 //
REUTERS
